Empowered Patient Podcast-logo

Empowered Patient Podcast

Health, Home & Life

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Location:

San Diego, CA

Description:

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Twitter:

@karenjagoda

Language:

English


Episodes
Ask host to enable sharing for playback control

AI Transforming Medicare Advantage Member Engagement with Dr. Saria Saccocio Essence Healthcare

10/24/2025
Dr. Saria Saccocio, Chief Medical Officer at Essence Healthcare, is using AI to enhance care and services for patients who are enrolled in Medicare Advantage programs. One application is to analyze data related to health equity, care authorization, and to address biases. Their AI agent is being used to interact with patients, offering them the option to access a human. Integration with wearables, such as the Oura Ring, focuses on identifying clinically useful information to prevent physicians from being overwhelmed by data. Saria explains, "Medicare Advantage plans are absolutely that. It's an advantage because of the additional benefits that exist and the opportunity to connect with our members is rather unique. In fact, what I'll share with you and the audience is that AI has been a focus for us and a priority as we continue to expand the focus on quality and engagement with our members so that they have their best quality life possible to them. AI is a major piece of this work to make that happen. I can give you a couple of examples. In fact, when it comes to health equity, CMS has recently required Medicare plans to ensure that we are analyzing our data through a health equity lens. This year, in fact, we're focused on authorizations, authorizations of care. We want to make sure that it is critical to our members and AI. I see an opportunity to recognize any blind spots or implicit bias." "I think that every human being has a capability for technology. And what's critical is that we meet them where they are, that we understand what they want, what they need out of technology. I think that works as well as providers. As you see all of these AI developers starting up companies and solving problems, the conversation that we're having every day at Lumeris and at Essence Healthcare is what does the patient want? What does that member need for quality of care? And then engage and include the providers in that conversation. What makes their job easier? Because one of the challenges with new technology is that we can also reach a point of technology exhaustion. So I'll give an example of our relationship with Oura ring, the wearable device that tracks for sleep, for health, for heart rate, and a number of different measures." #EssenceHealthcare #MedicareAdvantage #HealthAI #OuraRing #DigitalHealth essencehealthcare.com Download the transcript here

Duration:00:19:46

Ask host to enable sharing for playback control

Specialty Pharmacies Altering Rare Disease Care with Kerry Mello-Parker Shields Health

10/23/2025
Kerry Mello-Parker, Director of Rare Diseases and REMS programs at Shields Health Solutions, addresses the complexities and challenges faced by patients with rare diseases including diagnostic delays and limited access to medication. Using an integrated specialty pharmacy model, Shields works with pharmacists to have direct access to the EHR, enabling better patient monitoring, shorter time to initiate medication, tracking outcomes, and providing patients with a direct line of communication to their care team. Pharmacists treating rare diseases are also supported with specialized information on medication administration, side effects and complex billing. Kerry explains, "Shields Health Solutions is a specialty pharmacy accelerator. We partner with over 80 health systems across the United States. We support them in establishing and growing a specialty pharmacy. We help them to access critical medications. Some of them are not available at traditional pharmacies, and we support them in managing clinical quality care programs for their patients." "I'd like to step back a little and talk about what a rare disease is and how we define it. Currently, it is defined as a condition that affects fewer than 200,000 people. However, over 7,000 rare diseases exist. So when we do the math, we come to see that they are not so rare. And some estimates show that up to 10% of the US population may actually have a rare disease. And what I've seen is that there are really three main complexities of treating rare diseases and challenges that patients may face. One of them is that there is a lack of available treatment options when compared with more common diseases. So, for example, only about 10% of rare diseases have an FDA-approved treatment option, but that is changing. We have the Orphan Drug Act, which has actually changed the landscape. It has incentivized and facilitated the development of medications to treat rare diseases." #ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #RareDiseases #MedicationAdherence shieldshealthsolutions.com Download the transcript here

Duration:00:19:28

Ask host to enable sharing for playback control

AI-Driven Platforms Breaking Down Healthcare Data Silos with Ram Sahasranam Fold Health

10/22/2025
Ram Sahasranam, President and Co-Founder of Fold Health, has ceated a platform that integrates with the EHR to create an AI-driven interface that streamlines workflows, improves communication across the care team, and helps better manage patient care. Traditional EHR systems, while effective for documentation, were not built for proactive care and data sharing. With a focus on the patient and providers, Fold Health is integrating data sources and automating redundant administrative tasks helping to reduce clinician burnout and improve patient communication for scheduling and reminders. Ram explains, "The way to look at it is that empowering providers and patients need to go hand in hand. That is the fundamental reason why we called ourselves Fold Health, which is that healthcare needs to fold around the providers and the team supporting the providers and the patients and the families of the patients who are involved in the care. We have seen healthcare go from $1.6 trillion in spending to $5.3 trillion in spending this year. But in those 15 years, we haven't yet seen it fold around the two most important people, the provider or the patient, in terms of better outcomes or improving the burnout rates that clinicians and their teams face today." "So the fundamental challenge that we noticed was that multiple people were living in different systems and hence different silos from a data standpoint. So the clinician did not know what was happening with their care teams. The patient was living in a different system. If the patient goes to a specialist, the data comes in a compressed format to the physician in an easily digestible manner, which was a challenge. So what Fold does as a result of getting control of all these different nodes is that data can be used to summarize and provide things for the different teams in a quick, easily digestible manner." #Foldhealth #CareCoordination #CareDelivery #ConnectedCare #HealthTech #AI #HealthAI Fold.Health Download the transcript here

Duration:00:17:41

Ask host to enable sharing for playback control

Operational Efficiency Needed to Overcome Impact of Tariffs and Reimbursement Cuts on Struggling Hospitals with Ralph Kaiser ArcheHealth

10/21/2025
Ralph Kaiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs. ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care. Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver their products to hospitals and health systems, those will likely get passed through. It won't be huge incremental costs, so there will be additional costs due to tariffs. It depends on a couple of things. Do you have a strong contract that sort of embargoes your current price? Then maybe in the next contract term you'll see that pass through or the contract so the supplier to pass through, you'll see them. We're monitoring month by month the current or last month's spend was on these items, and do we see a chart impact by manufacturer by line." "One thing that I want to make sure we talk about, too, isn't just shared impact. So the cost to a hospital for devices and drugs averaged 8.9% more in 2024. So just by nature of the market raising its prices for goods that hospitals use to cover patient care, those moved up without tariffs 8.9% last year. We think we're tracking increases that are happening despite the tariff overlay or on top of the tariffs. We still think that the pressure on hospitals is due to the price of therapeutics, and is going to continue to go up, tariff or not. And so I want to mention that because this is the ongoing impact of the cost of MedTech and drugs that gets passed through to the consumer." #ArcheHealth #AIinHealthcare #HealthTech #HealthcareOperations archehealth.ai Download the transcript here

Duration:00:17:44

Ask host to enable sharing for playback control

First Treatment for Severe Respiratory Condition in Premature Babies with Dr. Marc Salzberg Airway Therapeutics

10/20/2025
Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia. Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment of severe respiratory conditions. And our first project is focusing on the respiratory condition that preterm neonates have, which is called bronchopulmonary dysplasia, and cannot be treated or prevented yet. It's a very severe condition. And that really triggered my interest in getting engaged because it's going to be a paradigm shift if we manage to bring this drug to market." "The protein that we're developing is an endogenous protein that we all have. In the past years or decade, it has been discovered that this protein has a very essential function in fighting inflammation and infection on a daily basis. Now, there are certain conditions or instances where the protein is low-functioning. For instance, in preterm-born babies, but also in adults with severe respiratory inflammation, with pneumonias, with asthma, or COPD. In all those cases where protein is low, those are the instances where you actually need it most. So, replacing it in those instances is a kind of logical rationale for the concept for the treatment that we're developing." #AirwayTherapeutics #BPD #InflammatoryDiseases #Zelpultidealfa #PrematureBabies #PretermBabies airwaytherapeutics.com Download the transcript here

Duration:00:18:17

Ask host to enable sharing for playback control

Leadless Pacemaker Technology Minimally Invasive Procedure That Lowers Surgical Risk with Wade Demmer Medtronic

10/17/2025
Wade Demmer, R&D Vice President at Medtronic, has developed a leadless pacemaker that is implanted on the heart through a minimally invasive procedure utilizing a catheter, potentially creating fewer complications and greater access for patients who could benefit from a pacemaker. This new design is a significantly smaller, safer, and longer-lasting device than traditional pacemakers and does not create a visible lump under the skin. Advancements in battery and computer technology have made the Micra next-generation pacemaker smarter, allowing cardiologists to treat a wider range of heart conditions. Wase explains, "So yes, pacemakers have been around for about seventy years. They've been helping people save lives, live fuller lives, and improve quality of life for that whole time. But you know, if you think about the history of a pacemaker, a pacemaker is a computer inside a little box that's implanted in the body. And like any computer, a computer from 70 years ago and a computer from today are very different. You know, 70 years ago, a pacemaker would've been about the size of a hockey puck, but even a little bit thicker. And nowadays, pacemakers are not much bigger than a couple of silver dollars stacked together. So we've made really big advances." "When you had those hockey puck-sized pacemakers or even modern-sized pacemakers, there's no place in the heart for it. And so they end up in the chest, and then there's a wire called the lead that goes down through the veins into the heart, and that's where the electricity gets delivered down to make the heartbeat. And that's also where the heart's electricity comes back up, so the pacemaker can know what's wrong. As we have pacemakers smaller and smaller, though, we suddenly reach a point where a radical downsizing is a possibility. And again, leveraging the computer technology of the world, getting a pacemaker inside the heart instead of in the chest." #Medtronic #CardiacCare #Pacemaker #LeadlessPacemaker #Micra #Cardiologists #HeartHealth #Innovation medtronic.com Download the transcript here

Duration:00:19:29

Ask host to enable sharing for playback control

Remote Affordable Robotic Surgery Transforming Access to Cardiac Procedures with Dr. Vishwa Srivastava SS Innovations International

10/16/2025
Dr. Vishwa Srivastava, APAC CEO of SSI, SS Innovations International, is a leader in telesurgery, using robotic surgery to extend surgical services in underserved areas. The SSI Mantra surgical robot is used for laparoscopic surgery and offers an affordable alternative to prevailing robotic solutions without compromising quality. Telesurgery has potential in remote operations and is also revolutionizing surgical training by providing real-time expert proctoring. Vishwa explains, "My father was one of the early global pioneers in robotic cardiac surgery, and he had actually helped Intuitive Surgical back in their early days get their FDA approval. And what he recognized very quickly was that through these minimally invasive robotic cardiac surgical procedures, 20% of his patients went home the next day, 50% in two days or less, and the average length of stay was 3.2 days. So, he became convinced after they twisted his arm to launch robotic cardiac surgical programs. And Dr. Fred Moll at the time was the chairman and founder of Intuitive Surgical, and he wanted to start on the heart because it was the most complex procedure to do a beating heart, totally endoscopic, bypass surgery. And he felt that if you could do that, then everything else would be simple." "The way that we look at remote robotic surgery, or what we call telesurgery, currently, we are the only company in India that has received formal regulatory approval from the CDSCO for both teleproctoring and telesurgery. The way that we look at teleproctoring and telesurgery, it's not like one rockstar surgeon sitting in one location operating omnipresent in a hundred different locations." "With teleproctoring and telesurgery, the way that we look at it is in addition to operating and extending expertise in the remote areas of the country, we look at teleproctoring and telesurgery the same way that doctors are trained in residency where you always have an attending in the room, the junior surgeon will be operating, and the goal of the proctor or the attending surgeon is to guide the junior surgeon to maturity." #SSInnovations #RoboticSurgery #Telesurgery #CardiacProcedures #HeartSurgery #Teleproctoring #RemoteSurgery SSInnovations.com Download the transcript here

Duration:00:21:17

Ask host to enable sharing for playback control

Reconstructive Surgery Reimagined with 3D Printed Custom Implants with Vikram Ahuja and Joe Promoppatam OsseoLabs

10/15/2025
Vikram Ahuja, Co-Founder and CEO, and Joe Promoppatam, Co-Founder and CTO of OsseoLabs, are utilizing 3D printing and AI to advance reconstructive surgery by enabling the creation of personalized, precision-fit implants and surgical instruments. Traditional surgery has relied on standardized implants made of titanium and involves lengthy operations. The OsseoLabs approach reduces surgical planning and operating time, improving patient outcomes by achieving a better fit and enhanced bone integration through the use of advanced implant materials. AI is used to automate and accelerate the design process for these custom devices, enabling a scalable and cost-effective approach to create complex, regulated medical devices. Vikram explains, "We want to use our engineering know-how, especially in 3D printing, to improve the quality of the outcome of the surgeries and also help the students to be able to offer a better solution at a speed, and also the outcome that is a little bit more precise. And that's what we have been working on for quite a long time. We want to use the knowledge of 3D printing, biomechanics, and also AI to help, especially in complex surgical cases. So both the patients and the surgeons are better off with the outcome. And the main gap that we are seeing here is not only in the Asian countries where we operate, but also in the US. And the use of 3D presented implants, even though it has been around for quite some time in the US, we still see a lot of gaps that can be improved in what materials are being used, and how the implants are designed. We help the surgeons and also the hospitals throughout this process." Joe elaborates, "Yes, for such a device, they all look the same way, but the patients look different. So we see this gap between the available instrumentation and the actual treatment that the surgeons want to conduct. And we want to break that barrier by being able to decide which instrument is required individually, and I mean that in the day, we could not do that. The price can be competitive because all the manufacturing technology is used to support production. But we have to depend on how they matured in the past few years. We are able to adopt the technology, which allows us to decide and print the instrument for specific care and specific surgery. I think the speed and cost become much more practical, and all we need to look into is the 3D printer. But eventually, when you come into something like customization, you talk about the speed. In terms of speed, it's not just the speed of how we make things, but it's about the speed of how we decide things. That's where we see the gap that we can fill using AI to split up the bedside process." #OsseoLabs #ReconstructiveSurgery #3DPrinting #PersonalizedImplants #MedAI OsseoLabs.com Download the transcript here

Duration:00:16:43

Ask host to enable sharing for playback control

AI Agent Automates Clinical Trial Recruitment Fast Tracking Drug Development with Trân Lê Grove AI

10/14/2025
Trân Lê, Co-Founder and CEO of Grove AI, was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand. Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his experience working in the hospital. We were working at Stanford, and there we were, computer scientists building a lot of internal tools for clinical trials, clinical research, as well as for the greater healthcare patient services. And that, combined with my experience trying to enroll in a clinical trial, really set us off to think deeply about how we can automate a lot of the manual workflows that exist today for patients and for providers, as well as for pharma in taking new drugs to market. Specifically, within that, we identified patient engagement and support, and prescreening to be an important part of ensuring that patients know where they're going and what to do when they're participating in these trials. And so we decided to really step out into the industry and change this process and make it an easier and more accessible experience for patients." "I would say that having worked inside a hospital and seeing all of this lead generation or getting people educated about the trial is an important aspect, and it's being done by a lot of the recruitment vendors as well as in-house teams out there. In addition to that, a bottleneck that previously has always been there now is possible to automate with agentic AI is actually doing the work of taking all the interest from different potential patients and helping them prescreen and understand the requirements of the trials, getting them to the right site, booking their transportation, reminding them about the appointments, and scheduling that appointment." "I would say that Grace, as we call her, is a digital staff or an AI agent - both are comparable terms to describe Grace. The difference is that Grace is trained on the trial, the requirements, and the IRB-approved script of that trial. So she really has the knowledge to be able to respond spontaneously in real time to any questions that the participant may have about the trial." #GroveAI #ClinicalTrials #PatientRecruitment #Pharma #HealthTech #DigitalHealth #AI #AgenticAI grovetrials.com Download the transcript here

Duration:00:19:06

Ask host to enable sharing for playback control

Multi-Target Approach Using Chemotherapy Drug Combo Shows Potential Across Cancer Types with Jeff Glazier General Oncology

10/13/2025
Jeff Glazier, CEO of General Oncology, is taking a unique approach to treating cancer by using older chemotherapy drugs with broad action but in novel combinations designed to avoid the incidental toxicity. Their primary drug in trials is GO-4 which is focused on shutting down DNA repair in cancer cells to overcome drug resistance. While testing in patients with stage 4 pancreatic cancer, this approach was designed to combat tumor heterogeneity by targeting fundamental processes like proliferation that are common to all cancer cells within a tumor. Jeff explains, "We're actually taking a different approach than a lot of companies are. And I would say there are really two approaches because we have two different things on, we have a clinical trial right now where we're using old chemotherapy drugs in a new way, and when you combine them together, you really get just a different result. We're trying to shut down DNA repair and kill cancer cells. But the other really interesting thing, and I think it’s underlying general vision, is chemotherapy drugs long ago had very broad action, and with broad action comes unwanted incidental toxicity. And over the years, it's been huge in the industry, or moving towards specific drugs that target specific things and have less incidental toxicity. The unfortunate side effect is that cancer cells can evolve around a drug if there's too much specificity. So we're taking a pretty novel approach with our business of going after drugs that have broad action, but we found a way, we believe, to do it in a way that doesn't have incidental toxicity." "I certainly feel that you want to have more than one attack. If you only do one, the cancer cells can evolve around it. The drug resistance approach I was referring to was what we call GO-4 in our clinical trial, and we're altering part of the cancer cells’ fundamental biology that is involved in DNA repair and shutting it down. But we're doing it in more than one way." #GeneralOncology #PancreaticCancer #CancerAwareness #MetastaticCancer #GO4Therapy #CancerResearch #InnovativeTherapies #DrugDevelopment generaloncology.com Download the transcript here

Duration:00:17:04

Ask host to enable sharing for playback control

Microlearning and Just-In-Time Tools Help Close the Policy-to-Practice Gap for Healthcare Workers with Dr. Arup Roy-Burman Elemeno Health

10/10/2025
Dr. Arup Roy-Burman, Founder and Chief Strategy and Medical Officer of Elemeno Health, is addressing the gap between established medical policies and actual frontline practice. The Elemeno microlearning platform provides just-in-time multimedia content, building confidence in high-risk, low-frequency procedures, helping support knowledge retention, and combating clinician burnout. This modern approach to learning caters to clinicians with shorter attention spans and the expectation of receiving information on the device of their choice when they need it. Arup explains, "My background is as an ICU physician, and I have practiced as an ICU director for 20-plus years. And the challenge that we had in our ICUs is how to keep our teams on the same page with constantly changing information? And on top of that, in the context of constantly changing staff, medicine is full of so many different practices, workflows, and procedures, and we expect our staff to know all of them and to be able to execute on each one of them at the time that they need to. But that's really unrealistic. There's no way that people can stay on top of it. All medical knowledge doubles every 73 days." "When we think about today's generational workforce, as we think about just those of us who have kids, we see that attention spans, as you said, are short. People don't want to sit through a whole classroom. They can't remember that. And the way that people want to learn now and the way that they do learn, it's like one of our clients put it, it's like the "TikTokification of education." How do we deliver information on a mobile device? How do we deliver it in short, bite-sized chunks? Multimedia that you can actually consume in context when you need it." #ElemenoHealth #DigitalHealth #HealthcareInnovation #Microlearning #NurseTraining elemenohealth.com Download the transcript here

Duration:00:24:17

Ask host to enable sharing for playback control

AI Platform Expands Clinical Trial Recruitment and Diversity with Kourosh Davarpanah Inato

10/9/2025
Kourosh Davarpanah, Co-Founder and CEO of Inato, is using an AI-enabled platform to transform participation in clinical trials. The existing clinical trial system is not seen as representative of the general population, and FDA directives have addressed this lack of diversity. The Inato platform features a marketplace approach that connects trial sponsors with a broader range of hospital sites, as well as an AI tool to assist doctors in identifying patients who are eligible for trials. Kourosh explains, "Our focus at Inato is to expand the number of patients who are able to participate in clinical research. If you think about how things have been done for the past decades, most of the patients who have the opportunity to participate are coming from the larger academic hospitals. And what this means is that typically, 5% of the sites, meaning 5% of the hospitals running research, run about 70% of all the trials globally. So this has an impact not only on the number of patients that can actually participate in trials, but it also has an impact on the type of patients. So, typically, those are going to be white patients, richer patients. And so it has a big impact also on equity and on the diversity--and ethnic diversity especially--of patients participating." "We have two pieces of the platform. The first piece is that we're helping connect the hospitals running the trials with trials that are being run by the sponsors. So the way this works is similar to marketplaces like Airbnb, where you have the sponsor that can share any number of upcoming trials. We enable the sites to discover all the trials on the platform and showcase, based on their profiles, how many trials they have done in the past, what is the makeup of the team and doctors, etc. We're able to allow them to get selected in trials that they otherwise wouldn't be able to get selected for. So this is the first piece of it, really connecting the sites and the trials. And increasingly with AI, we've started supporting sites in actually identifying patients at scale. And this has really been a massive tech shift, where the latest generations of LLMs are able to accurately identify patients eligible for any trial with over 95% accuracy." #Inato #ClinicalTrials #ClinicalRearch #AI #MedAI #DrugDevelopment Inato.com Download the transcript here

Duration:00:19:22

Ask host to enable sharing for playback control

Healthcare Lab Sample Logistics and Need to Identify and Eliminate Errors with Javier Cuello H+Trace

10/8/2025
Javier Cuello, Founder and CEO of H+Trace highlights the significant and often overlooked problem of errors in the handling of medical samples. Issues like mislabeling, contamination, and improper shipping conditions are responsible for a majority of lab result errors, potentially leading to patient misdiagnoses. The H+Trace solution uses wireless sensors and AI to track samples, generate high-value data, and predict where errors are likely to occur. Working in Latin America and Central America has provided the company with experience in utilizing drones for shipping medical samples and organs to remote and hard-to-reach areas, while maintaining sample integrity. Javier explains, "It all started for me when a very close friend of mine was misdiagnosed with diabetes while she was pregnant. And when I started digging into this problem, what we found out is that most lab tests today are highly reliable. Once the sample reaches the analyzer, the real danger lies in the logistics of collecting, labeling, and transporting samples prior to that. While not every mistake hurts, the patient studies showed that about 2% to 5% of errors are clinically significant, and this means over 9,000 patients every day in the US risk misdiagnosis, late treatment, and unnecessary procedures or even life-threatening consequences, all because of failures in the pre-analytic logistics." "It's a quite new problem because over the past decades, laboratories have invested heavily in laboratory equipment and training, but the logistics of sample handling have seen little innovation. That is why roughly two-thirds of errors still occur in the pre-analytical phase." "But the reality is that most laboratories don't even know under what conditions the transport takes place. Even some of the most important labs simply receive the sample processing and send the results. So we're working with a laboratory that addresses this kind of problem, which started with labor. They have their own logistics. We started in Latin America and Central America, and now we're about to launch in the US because this is a very big problem in the US." #HTrace #Logistics #LabSamples #Sensors #ShippingLabSamples h-trace.com Download the transcript here

Duration:00:22:37

Ask host to enable sharing for playback control

AI Tools Streamlining Clinical Workflow Improving Patient-Physician Relationship with Kyna Fong Elation Health

10/7/2025
Kyna Fong, Co-Founder and CEO of Elation Health, is developing AI tools that prioritize patient care and automate documentation and referrals to help alleviate physician burnout and improve the patient-provider relationship. Kyna emphasizes the critical role of interoperability in effective primary care, enabling primary care physicians to coordinate care. She also noted the recent White House initiative on interoperability, which encouraged the private sector to cooperate in data-sharing initiatives, now that AI can be used to overcome technical issues of data integration and analysis. Kyna explains, "Clinical-first is not new for Elation. It's actually our founding product philosophy. When we first started building Elation, what we observed was that so many tools that were built for physicians to use and their electronic health records were very much oriented around billing needs and, in a lot of ways, followed a billing-first philosophy. And so we created Elation to really focus on clinical first, which means putting patient care first and foremost." "The way that we are approaching AI is as a tool. It's a tool in our toolkit. It's a how and when we think about all the pressures and burdens on physicians, especially primary care physicians, that prevent them from being able to focus on their patients. We take each of those and think about, well, how can AI make this easier? And so there are a variety of areas where we've deployed AI to help our customers. There are the clear, fairly pervasive ones today that start with something like an ambient scribe that helps with documentation, saving multiple hours per day. It's radically transformative." #ElationHealth #AI #MedAI #PrimaryCare #Physicians #EHR #HealthIT #DigitalHealth elationhealth.com Download the transcript here

Duration:00:20:31

Ask host to enable sharing for playback control

Scientists Confront Funding Crisis with Collaborations to Combat Economic Pressures with Hamid Ghanadan LINUS

10/6/2025
Hamid Ghanadan, CEO of LINUS, discusses the findings of the company's recent state-of-the-science research, a semiannual survey that tracks sentiment and confidence within the life sciences. Notably, a growing gap in optimism exists between academic and biopharma scientists. As a result, academics are seeking partnerships at a new level due to economic pressures from grant cancellations, the need for multidisciplinary collaboration to solve complex problems, and the desire for a stronger collective voice. AI was identified as the top priority for academia and biopharma, as is the need to improve communication with the public about scientific discoveries and medical advancements. Hamid explains, "We started the state-of-the-science research four years ago, so this is the eighth time that we've done it. And what we're really doing is measuring consumer confidence within the life sciences. So we track sentiment, we track funding, we track barriers and opportunities, as well as purchase intentions. And we do it every six months for the coming six months of the year." "So here you have to take into consideration that we talk to scientists globally in this survey, and we talk to them from a variety of different settings and environments. So while about half of our respondents are from academic institutions around the world, the other half are in a variety of industries, mostly biopharma. And we see here that there's a shift, there's a difference in sentiment and in optimism, in outlook, in interest in science, in the applicability of science, and how these different groups are managing it. As you can imagine, the academics are feeling a lot more pressure." "The consumer sentiment is lower, and there's definitely more fear in that cohort of scientists. Biopharma is actually surprisingly more resilient, more forward-looking. So on the biopharma side, what we're seeing is that there's actually surprising resilience and there's forward-looking intentions. And we see that scientists are actually looking forward to applying new techniques and new technologies that are coming online, and they have more confidence in their ability to make progress for the second half of 2025." #LINUSGroup #Lifesciences #Healthcare #AIHealthcare #Stategy #Scientists #AI #MedAI thelinusgroup.com Download the transcript here

Duration:00:18:05

Ask host to enable sharing for playback control

Comprehensive Cancer Care Navigation Improving Patient Outcomes with Dr. Kamal Golla Evolent

10/3/2025
Dr. Kamal Golla, Vice President of Clinical Technologies and Performance at Evolent, highlights the complexities of cancer care and the need for care navigation to address medical, emotional, financial, and logistical challenges. This comprehensive approach leads to improved treatment adherence and patient satisfaction while reducing emergency room visits and hospitalization. The care team serves as an extension of the medical decision-makers, helping to manage care across multiple specialists, advising on overcoming side effects, and reducing logistical hurdles to ease the burden on physicians and caregivers, ultimately improving patient outcomes. Kamal explains, "Cancer care navigation is really about creating a roadmap for patients. It's making sure they're not left alone to piece together appointments, interpret side effects, or figure out how to pay for medications. The role of a navigator here is really to guide them through the whole journey. That includes the medical components that many folks are familiar with, but also the emotional, financial, and logistical components that come with a cancer diagnosis. The evidence is really clear, given that more than half of emergency department visits and nearly a quarter of hospitalizations related to cancer care are actually avoidable, that responding rapidly to these situations is key." "In our navigation program, we are rooted in patient-centric navigation, meaning we ask them what the transportation difficulties are that they might face. Who is your caregiver and their support? What do you do for work? What are your cultural and religious beliefs? All of those play a big part in dealing with the new diagnosis of cancer. We want all of that information to be able to provide a very personalized journey." #Evolent #Oncology #CancerCare #CareNavigation #HealthcareInnovation #DigitalHealth #PersonalizedCare #PatientCenteredCare #Evolent #Careology Evolent.com Download the transcript here

Duration:00:17:48

Ask host to enable sharing for playback control

Digital Health Platform Coordinating Care to Improve Treatment and Outcomes for Digestive Disorders with Bill Snyder Cylinder

10/2/2025
Bill Snyder, CEO and Founder of Cylinder, is addressing the high prevalence of digestive health issues using a virtual care model to provide access to a coordinated care team, including dieticians and health coaches, to offer personalized care plans. GI conditions are complex and involve a combination of genetic predisposition, environmental factors, and dietary influences. There are strong correlations between the gut and brain, as well as digestive health and various physical and mental conditions. Cylinder fills a gap in traditional GI care, where physicians often lack extensive nutritional training. Bill explains, "First and foremost, we think about the patients that we serve, and the patients that we serve come to us from across the country. We serve patients in every state across the US, and they suffer from a variety of GI-related conditions. That's things like ulcerative colitis, Crohn's disease, irritable bowel syndrome, and GERD. It's also a large population who don't have a formal diagnosis, but are symptomatic of GI conditions. So they may have chronic bloating, chronic constipation, and chronic heartburn, and they may not know what the underlying cause is. And then we also reach those members through our clients, which are large self-funded organizations and health plans. People traditionally gain access to Cylinder as part of their employee benefits package." "But there's also a lot that we continue to understand in terms of our overall digestive health system connection. The gut-brain axis, which serves as a bilateral feedback loop between the gut and the brain, is where we found that your digestive health often correlates with your mental health, and vice versa. So we know that some of the reasons for the onset of these conditions can be genetic, but to your point, we're also seeing a lot of impact from our environment and certainly from the foods we eat. And so as you think about the American diet, and as you think about how that's changed over the past several decades, we're seeing an increase in the incidence of these conditions and an increase in people who are presenting with these symptoms and not really sure where to go or what to do." #CylinderHealth #GIhealth #digestivehealth #cylinderhealth #GIcare #virtualhealth #employeebenefits cylinderhealth.com Download the transcript here

Duration:00:17:38

Ask host to enable sharing for playback control

How Agentic AI is Transforming Healthcare Call Centers with Pat Michael Nebraska Medicine

10/1/2025
Pat Michael, Director of Patient Contact Services at Nebraska Medicine, highlights the challenges of high-volume patient contact centers and how agentic AI can improve operational efficiency, enhance patient access, and allow human agents to focus on more complex and critical calls. The AI agent offers patients self-service options for scheduling, cancellations, and medication refills, resulting in a 40% reduction in call volume to human operators. Integrating AI into the contact center also enables the prioritization of time-sensitive calls, such as those related to organ transplant coordination. Pat explains, "I'm the Patient Contact Services Director for Nebraska Medicine, which means I oversee our three main contact centers. They're our ambulatory contact center, which takes and schedules all the calls for our ambulatory clinic, and our radiology contact center, which schedules all of our outpatient radiology services. And then our medical communication center, which is our 24-hour-a-day, seven-day-a-week operation with our hospital operators and a group of triage nurses." "So, some of the challenges that we had are that one of the big things is that we deal with the sheer volume of calls coming into the contact center. And so through the three contact centers, we have about 2.5 million calls that come in, but they're not evenly distributed. They come in when they come in. And so the key to success is managing all these complex calls while ensuring accuracy in the call handling. And what does that mean in the simplest terms? You have to have time to handle the calls accurately. Are we actually staying ahead of the volume, or are we just trying to catch up?" #NebraskaMedicine #ActiumHealth #AIAgents #PatientEngagement #healthtech #AgenticAI #automation Nebraskamed.com Download the transcript here

Duration:00:19:11

Ask host to enable sharing for playback control

Autologous Cell Therapy for Heart Disease Transformed with Point-of-Care Processing and 3D Imaging with Dr. Peter Altman BioCardia

9/30/2025
Dr. Peter Altman, President and CEO of BioCardia, is focused on treating ischemic heart failure and chronic myocardial ischemia using autologous cells from the patient's bone marrow. The company has developed a cost-effective model that utilizes a pre-procedure diagnostic to select the optimal patients for this point-of-care system, which processes their cells in a single procedure. A key technology is the Helix catheter system, which enables minimally invasive delivery of cells into the heart, aided by the Heart3D Fusion imaging platform that provides a 3D map for precise cell delivery. Peter explains, "BioCardia's focus is on ischemic etiology of heart disease. This is heart disease that results from poor perfusion, typically following, for example, a heart attack, which is an ischemic disease. And the two diseases we're working on are ischemic heart failure, which is often characterized by a large dilated heart. And in the second is chronic myocardial ischemia, which is characterized by what's called refractory angina or chest pain that actually can be incredibly severe. And so are our focus areas. And we're advancing cell therapies that have been shown to inherently improve the cells we're looking at, which are cells from the bone marrow space, the mononuclear cells that contain the CD34 and CD133 cell populations. They're actually involved in forming new microvasculature and supply." "What we've done is come at it from a different perspective. Instead of selecting the cells and then manufacturing in a remote facility, we have a pre-procedure diagnostic that enables us to select the patients who have appropriate cells and then process them with a point-of-care cell processing platform, which involves just a simple disposable cartridge. And then we can treat these patients in a standard interventional cardiology setting at relatively low cost compared to all cell therapies." #BioCardia #HeartDisease #AutologousCellTherapy #CellTherapy #3DImaging #Heart3DFusion #CardiAMP biocardia.com Download the transcript here

Duration:00:24:13

Ask host to enable sharing for playback control

Using AI-Enhanced Mammography to See Through Dense Breast Tissue with Marissa Fayer DeepLook Medical

9/29/2025
Marissa Fayer, CEO of DeepLook Medical, points out the challenges of detecting breast cancer in dense breast tissue using mammography. The DeepLook DP Precise platform is a visual intelligence tool to help radiologists see inside dense tissue more clearly without disrupting their workflow, potentially reducing the need for additional tests or biopsies. A recent FDA mandate requiring providers to inform patients about their breast density has increased patient demand for better screening tools Marissa explains, "We're focused on breast imaging, and it's very specifically in dense breasts, because unfortunately, with dense, it's like seeing a cotton ball in the cloud. Radiologists have a really hard time seeing that in standard ways. This is a known problem. I developed the three mammography systems, so I absolutely know that it's a problem. We help radiologists visualize better with visual intelligence to be able to see inside these mammograms so that they potentially don't have to send their patients back for additional ultrasounds, other mammograms, or even biopsies." "So dense breasts show up white on mammograms, and cancer shows up white. So again, it's the analogy of the cotton bowl in the cloud. It might be there, but it might not be. The cloud is just hiding the cotton ball. This is just how X-ray technology is. It's been a problem and known since its inception, and unfortunately 45% to 50% of all women have dense breasts. And so, this is a very common problem, and there's nothing anybody can do. You can't diet or change the way your body composition is. In reality, this is just an additional add-on to existing screening that is a standard of care to help women." #DeepLookMedical #WomenInHealthTech #BreastCancerAwareness #DenseBreastTissue #AIinHealthcare #DigitalHealth #HealthEquity #EarlyDetection #EmpoweredPatients #PatientCenteredCare #WomensHealth #Breastcancer deeplookmedical.com Download the transcript here

Duration:00:17:19